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Background: Quality of life (QoL) is an important measure and outcome within chronic disease management and
treatment, including substance use disorders (SUD). The aim of this paper was to investigate correlates of poorer
QoL of individuals entering SUD treatment in Norway, in order to identify subgroups that may most benefit from
different interventions.
Methods: Twenty-one treatment facilities invited all incoming patients to participate. Five hundred forty-nine
patients who enrolled between December 2012 and April 2015 are analyzed. QoL, substance use, mental and
physical comorbidities, and exercise behaviors were measured. Multinomial regression analysis was used to
determine variables significantly associated with poorer QoL.
Results: The majority of both genders (75 %) reported “poor” or “very poor” QoL at intake. Depression showed a
strong association with poor QoL (relative risk ratio [RRR] 3.3, 95 % confidence interval [CI] 1.0–10.3) and very poor
QoL (RRR 3.8, 1.2–11.8) among women. Physical inactivity among men was associated with very poor QoL (RRR 2.0,
1.1–3.7), as was reporting eating most meals alone (RRR 2.6, 1.4–4.8). Evaluating one’s weight as too low was also
associated with poor QoL (RRR 2.0, 1.0-3.9) and very poor QoL (RRR 2.0, 1.1–3.7) among men. Consuming
methadone/buprenorphine was a protective factor for men reporting poor QoL (RRR 0.5, 0.3–0.9) and very poor
QoL (RRR 0.4, 0.2–0.9), as well as for women reporting very poor QoL (RRR 0.2, 0.0–0.6).
Conclusions: Factors associated with poorer QoL among other healthy and clinical populations, such as
impaired social and physical well-being and psychological distress, were also seen associated in this sample.
Treatment should be targeted towards patients with these particular vulnerabilities in addition to focusing on
substance-related factors, and interventions proven to improve the QoL of other populations with these
vulnerabilities should be explored in a SUD context.
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Treatments for chronic diseases are increasingly evaluated
through subjective patient assessments on outcomes other
than morbidity and mortality, and quality of life (QoL)
stands out as the most common and a relevant measure-
ment. QoL is a subjective appraisal of a patient’s life in
that instant: how satisfied the patient is with their current
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emphasized domains [1]. The substance use disorder
(SUD) treatment field has until recently less systematically
collected and prioritized the QoL of patients, in compari-
son with other medical fields [2]. Importantly, QoL mea-
sures add patients’ subjective assessments of the impacts
that SUD and its treatment can have on their lives [3].
Such measures privilege the patient in determining whether
their employment status, health, and family contact, for ex-
ample, are satisfactory or not. QoL measures may also help
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Individuals with SUD typically report significantly
poorer QoL than the general population and as low as
those with other serious psychiatric disorders [5–8].
Poor QoL may also be a predictor of treatment readi-
ness; two qualitative studies have shown that the desire
to redress the negative effects of a SUD on a patient’s
life and improve their QoL is a more explicit goal of
treatment among patients than is reducing substance
use itself [9, 10]. Interestingly, poor QoL has not been
consistently predicted by SUD-specific characteristics,
such as the types of substances used, frequencies of
use, and lengths of problematic usage [7, 11]. Yet QoL
plays a role in recovery from a SUD: Laudet et al. found
that higher QoL at treatment discharge predicted ab-
stinence better than traditional SUD characteristics [9].
In addition to measuring QoL for its own sake, as a
subjective measure of functioning [12], exploring and
addressing the dissatisfaction with various life domains
that impair QoL may improve abstinence outcomes and
help patients access a fuller range of health benefits after
treatment.
Few consistent predictors of QoL have been found,
speaking to the global nature of this measure. However,
good mental health appears to be a strong protective fac-
tor among opioid dependents, alcohol dependents, and
polysubstance users [11, 13, 14], dual-diagnosis patients
[15], and non-SUD populations [16], perhaps because of
the far-reaching effects that psychiatric symptoms and
disorders exert on an individual’s life. Along with better
mental health, exercise can also have an enhancing effect
on QoL among healthy and clinical, non-SUD populations
[17–20]. Trials with the SUD population measuring QoL
after exercise are lacking, and the mechanisms by which
exercise affects QoL are still unknown. A reduction of
comorbid risk factors [21], mediation of the deleterious
effect of chronic physical conditions on QoL [22, 23],
and improved self-efficacy and other psychological con-
structs [24] have been suggested as mechanisms. Interest
in exercise overall among the SUD population has led to
evidence suggesting exercise plays a role in improving
abstinence rates and other substance outcomes such as
craving, decreasing depressive and anxious symptoms, and
improving physical condition (see Zschucke et al 2012
[25] for a review).
The interaction of the social environment with the
development of a SUD and treatment trajectory have
been of interest since the 1980’s, and the nuances of social
factors progressively explored. For example, the detrimen-
tal effects of a substance-using network on abstinence ap-
pear to outweigh both the quantitative and qualitative
support received in that network [26, 27]. Furthermore,
the composure and impact of social networks appears todiffer between genders; substance use among partners and
family members has stronger negative effects on women’s
treatment outcomes than on men’s [28–30]. Women and
men also have different factors, including social variables,
which set them at risk for relapse or treatment drop-out
[27]. Less research has been devoted to social factors’ im-
pact on QoL, despite low QoL being another drop-out risk
factor [9], and this relationship does not seem to have
been investigated with a gender lens. In this article, we
therefore describe the QoL of persons presenting for SUD
treatment, and investigate gender differences in substance,
health, and social factors associated with poorer QoL.
More knowledge of these factors, which are also determi-
nants of successful treatment outcomes, will be able to
guide treatment providers towards improved and targeted
clinical practices.
Methods
Participants and setting
Cross-sectional data were drawn from the Norwegian
cohort of patient in opioid maintenance treatment study
(NorComt), a multi-center study involving 21 treatment
facilities throughout Norway [31]. Facilities provided
inpatient and/or outpatient treatment, both opioid
maintenance treatment and medication-free. Data were
collected 2012–2015 from patients when they entered
facilities, via structured, face-to-face interviews by facil-
ity staff which took an average of 90 min. The research
team trained facility staff in use of the questionnaires
through a series of group workshops and interview
guides. The only inclusion criterion was admittance into a
substance use disorder treatment facility within the past
twelve weeks, regardless of primary substance type(s). A
total of 1416 patients were identified as potentially rele-
vant for this study. Mainly due to logistical difficulties at
the facilities, 318 patients were not informed about the
study or invited to participate, resulting in their ineligibil-
ity. Seventy-four percent of the 746 eligible patients agreed
to participate, while 129 declined and 68 either did not
respond or did not meet for the interview. In total, 549
participants enrolled from the 21 facilities.
Measures
Overall QoL was measured by a single item asking,
“how would you rate your quality of life?” [31]. Respon-
dents answered using a five-point Likert-type scale from
“very poor” to “very good.” This question is the same as
the global measure included in the World Health Orga-
nization’s brief and full QoL tools (WHOQOL-BREF and
WHOQOL-100, respectively) [1, 32], selected for its
discrete time burden and reliability with multiple-item
QoL scales [33]. As a generic question validated among
a variety of healthy and clinical groups, including in
Norway [34, 35], it enables the comparison of patients’
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ded within their particular environmental contexts [1].
The interview questionnaire also included excerpts
from the EuropASI, a validated version of the Addiction
Severity Index adapted for European use [36], to collect
substance variables and information on social networks.
Patients selected substances from a list of 18 that in-
cluded, among others, alcohol, cannabis, heroin, and
methadone/buprenorphine. The two subscores of the
Hopkins Symptoms Checklist-25 were used to assess
mental health. A subscore above 1.0 on the 10-item
anxiety subscore indicated symptom levels of clinical
anxiety, while a subscore above 1.0 on the 15-item de-
pression subscore indicated clinical depression [37].
Regular physical activity was defined as more than
twice weekly over the past six months. In addition, di-
chotomous sociodemographic independent variables
included civil status (“single” or “married/partnered”),
Norwegian-born, unemployed, educational attainment
of primary school or less, and having at least one child.
“With whom do you eat most of your meals?” was used as
a proxy for social contact [38, 39], and dichotomized into
“alone” or, if patients selected friends, families, or others,
“with others”.
Analysis
Bivariate analyses tested the individual association of
each independent variable with each gender’s overall QoL
and between each gender, using chi-squares and t-tests or
Mann-U Whitney tests, as appropriate and according to
distribution. Independent variables were selected based on
previous research into relevant QoL-determinants among
SUD patients and new variables of interest. These vari-
ables included: treatment type (opioid maintenance treat-
ment or medication-free inpatient), most recently used
substance by type, comorbid mental illness (depression or
anxiety), chronic somatic illness (including cancer, chronic
obstructory pulmonary disease, and HIV), self-reported
physical inactivity and satisfaction with one’s weight, social
network variables, and sociodemographic variables.
We performed multinomial logistic regression analysis
for each gender including independent variables with a
relationship (p < 0.1) to QoL in bivariate analysis, and
age was treated as a continuous covariate. As the distri-
bution of scores did not meet the stringent requirements
of ordinal logistic regression, the five-point Likert scale
of “very poor”, “poor”, “neither good nor poor”, “good”,
and “very good” was collapsed into three categories
(“very poor”, “poor”, and “neutral/good/very good”) to
enable multinomial logistic regression. As the majority
of patients reported “poor” or “very poor” QoL, these
categories were analyzed separately – against the refer-
ence category of “neutral/good/very good” – in order to
determine which variables were associated with theworst-off. The outcome measure was the relative risk
ratio (RRR) with confidence interval using the category
neutral/good/very good as the reference.
SPSS version 22 was used for all statistics.
Results
Sample descriptives
As displayed in Table 1, this heterogeneous sample was
comprised of 156 women (28 %) and 393 men (72 %),
with an average age of 33.7 (SD 9.9) Most reported being
single (93.4 %), unemployed (87.2 %), and having less
than a secondary education (59.4 %). Symptoms of clin-
ical anxiety (56.7 %) were common, as were symptoms
of clinical depression (56.2 %) and additional somatic
chronic illnesses. Regular physical activity was reported
by 41.7 % of participants, and about half said they were
dissatisfied with their current weight (54.4 %). The
majority were polysubstance users (91.5 %) and had
previous SUD treatment experience (92.3 %). The
most common substance used in the past six months
was heroin (by 24.4 % of participants), followed by
OMT medication (21.5 %), amphetamines (19.6 %),
cannabis (16.9 %), and alcohol (7.9 %). About half said
their social network was mainly comprised of other
substance users (50.5 %), compared to one-third who
reported a substance-free network (32.2 %) and 17.1 %
reporting no network at all. Spending mealtimes alone
was reported by 45.9 %, while 25.8 % ate with family,
16.9 % with friends, and 11.1 % with others.
Current overall QoL and other characteristics by gender
Men and women’s ratings of their overall QoL skewed
towards poorer ratings, as seen in Fig. 1. Approximately
three-fourths of both genders self-reported their QoL as
“very poor” or “poor”, and 25 % rated it “neutral” or
higher. There were no significant differences in the dis-
tribution of women and men’s QoL.
Correlates of poor overall QoL by gender
The distribution of QoL (in three categories) according
to independent variables is displayed in Table 2. Among
both genders reporting very poor QoL, the majority also
reported symptoms of clinical anxiety (68.9 % of men
and 69.1 % of women) and depressive symptoms (64.8
and 70.6 %, respectively). Both men and women who re-
ported methadone/buprenorphine as their “most-used
substance” were more likely to report good, neutral, or
very good QoL (33.0 and 31.3 %, respectively) than very
poor QoL (18.0 and 7.2 %).
Most men who reported good, neutral, or very good
QoL were physically active (55.1 %), and most reported
being satisfied with their weight (61.3 %). While men
with a substance-using network represented about half
of each QoL category (45.9 % of those with good, neutral,
Table 1 Sample descriptives of incoming substance use
disorder patients in Norway, 2012–2015
n (%)
Age (mean) 33.7 (SD 9.9)
Female 156 (28.4)
Single 512 (93.3)
Norwegian-born 496 (90.7)
Primary education or less 323 (59.4)
Unemployed 479 (87.2)
Has children 245 (45.6)
Clinical anxiety symptoms 303 (56.7)
Clinical depression symptoms 300 (56.2)
Chronic disease(s) 398 (72.5)
Physically inactive 319 (58.3)
Physically active 228 (41.7)
Weight evaluation
Satisfied with weight 235 (45.6)
Considers self underweight 126 (24.5)
Considers self overweight 154 (29.9)
Medication-free treatment 266 (48.5)
OMT 283 (51.5)
Injected, past 4 weeks. 196 (35.8)
Substance user category
Prescribed OMT and/or medications only 8 (1.5)
Substance- and medication-free 4 (0.7)
Single-substance user 34 (6.3)
Polysubstance user 497 (91.5)
Previous SUD treatment in months, median
Inpatient 8.0
Outpatient 13.5
Most used substance, past 6 months
Alcohol 43 (7.9)
Cannabis 92 (16.9)
Heroin 133 (24.4)
Methadone/buprenorphine 120 (21.5)
Benzodiazepine 38 (7.0)
Amphetamine 107 (19.6)
Social network
Substance-free 176 (32.2)
Substance-using 277 (50.6)
Socially isolated 94 (17.2)
Stable recent living situation 428 (78.5)
Eats most meals alone 245 (45.9)
East with someone else 289 (54.1)
Recent living situation
Homeless 56 (10.2)
Table 1 Sample descriptives of incoming substance use
disorder patients in Norway, 2012–2015 (Continued)
Temporary housing 26 (4.7)
Institution 127 (23.2)
Owned or rented 267 (48.7)
Other 72 (13.1)
SUD substance use disorder, OMT opioid maintenance treatment
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49.6 % of those with very poor QoL), socially isolated men
were represented more in the very poor QoL category
(25.2 %) and men with a substance-free network were
represented more in the very good, good, or neutral
QoL category (38.8 %). Finally, 63.3 % of men with very
poor QoL also said they ate most of their meals alone,
while 61.1 % of men reporting the highest category of
QoL ate with others.
Table 3 below displays the association of variables,
selected for their significant bivariate relationships to
QoL displayed in Table 2, with reporting poor and very
poor QoL. In the final multinomial logistic regression,
experiencing symptoms of clinical depression was strongly
associated with poor QoL (RRR 3.3, CI 1.0–10.3) and very
poor QoL (RRR 3.8, CI 1.2–11.8) among women.
Physical inactivity had an association to reporting very
poor QoL (RRR 2.0, CI: 1.1–3.7) for men, and judging
their weight to be inappropriately low was associated
with both poor QoL (RRR 2.0, CI: 1.0–3.9) and very poor
QoL (RRR 2.0, CI: 1.1–3.7). The trend towards poor QoL
among men who viewed their weight as too high (RRR
2.0, CI: 0.9–3.9) and who were not physically active (RRRFig. 1 Quality of life distribution of incoming substance use disorder
patients in Norway, 2012–2015. Detailed legend: Quality of life was
skewed towards negative ratings among this sample of entering
Norewgian substance use disorder patients. Seventy-five pecent
rated their quality of life as “poor” or “very poor”, and distributions
did not vary by gender
Table 2 Overall quality of life (QoL) of patients entering substance use disorder treatment in Norway, 2012–2015
Men’s overall QoL Women’s overall QoL
very good/good/neutral
n = 99
poor
n = 168
very poor
n = 124
very good/good/neutral
n = 33
poor
n = 54
very poor
n = 69
n (%) n (%) n (%) n (%) n (%) n (%)
Age (mean (SD)) 34.3 (10.3) 33.4 (9.1) 32.3 (9.6) 31.6 (10.9) 35.4 (11.1) 33.8 (10.5)
Single 90 (91.8) 157 (95.2) 117 (95.1) 30 (93.8) 48 (90.6) 63 (92.6)
Norwegian-born 86 (87.8) 149 (91.4) 117 (95.1) 30 (93.8) 48 (90.6) 58 (84.1)
Primary education or less 56 (57.7) 94 (57.3) 77 (62.6) 19 (59.4) 32 (61.5) 41 (61.2)
Unemployed 85 (87.6) 138 (85.7) 113 (93.4) 27 (84.4) 48 (90.6) 62 (91.2)
Has children 47 (50.5) 70 (42.7) 48 (40.0) 18 (58.1) 26 (50.0) 30 (44.1)
Clinical anxiety symptoms 48 (49.0)* 80 (49.7) 84 (68.9) 13 (41.9)* 30 (56.6) 47 (69.1)
Clinical depression symptoms 44 (44.9)* 84 (52.2) 79 (64.8) 11 (35.5)* 33 (62.3) 48 (70.6)
Chronic disease(s) 71 (72.4) 113 (68.5) 91 (74.0) 26 (81.3) 42 (79.2) 53 (76.8)
Physically inactive 44 (44.9)* 99 (60.4) 76 (61.8) 20 (62.5) 21 (39.6) 25 (36.2)
Physically active 54 (55.1) 65 (39.6) 47 (38.2) 12 (37.5) 4 (8.2) 9 (14.8)
Weight evaluation
Satisfied with weight 57 (61.3)a 67 (43.2) 52 (44.4) 17 (53.1) 17 (34.7) 22 (36.1)
Considers self underweight 21 (22.6) 48 (31.0) 38 (32.5) 4 (12.5) 4 (8.2) 9 (14.8)
Considers self overweight 15 (16.1) 40 (25.8) 27 (23.1) 11 (34.4) 28 (57.1) 30 (49.2)
Medication-free treatment 42 (42.9) 80 (48.5) 68 (55.3) 12 (37.5) 23 (43.4) 39 (56.5)
OMT 56 (57.1) 85 (51.5) 55 (44.7) 20 (62.5) 30 (56.6) 30 (43.5)
Injected, past 4 weeks. 37 (37.8) 55 (33.5) 44 (36.1) 11 (34.4) 16 (30.2) 29 (42.0)
Substance user category
Prescribed OMT and/or medications only 4 (4.1) 1 (0.6) 1 (0.8) 2 (6.3)a 0 (0.0) 0 (0.0)
Substance- and medication-free 1 (1.0) 3 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Single-substance user 7 (7.2) 12 (7.4) 6 (5.0) 3 (9.4) 2 (3.8) 4 (5.8)
Polysubstance user 85 (87.6) 147 (90.2) 113 (94.2) 27 (84.4) 51 (96.2) 65 (94.2)
Previous SUD treatment in months, median
Inpatient 6.0 4.0 5.0 10.5 4.0 5.5
Outpatient 4.0 6.0 9.0 13.0 12.5 12.0
Most used substance, past 6 months
Alcohol 7 (7.1) 9 (5.5) 7 (5.7) 2 (6.3) 6 (11.3) 12 (17.4)
Cannabis 14 (14.3) 37 (22.4) 27 (22.0) 2 (6.3) 6 (11.3) 5 (7.2)
Heroin 21 (21.6) 34 (20.9) 30 (24.6) 10 (31.3) 15 (28.3) 19 (27.5)
Methadone/buprenorphine 32 (33.0)* 37 (22.7) 22 (18.0) 10 (31.3)** 12 (22.6) 5 (7.2)
Benzodiazepine 6 (6.1) 10 (6.1) 7 (5.7) 1 (3.1) 6 (11.3) 7 (10.1)
Stimulant 16 (16.3) 33 (20.0) 28 (22.8) 7 (21.9) 7 (13.2) 21 (30.4)
Social network
Substance-free 38 (38.8)a 64 (38.8) 31 (25.2) 14 (45.2) 12 (22.6) 14 (20.6)
Substance-using 45 (45.9) 76 (46.1) 61 (49.6) 14 (45.2) 32 (60.4) 45 (66.2)
Socially isolated 15 (15.3) 25 (15.2) 31 (25.2) 3 (9.7) 9 (17.0) 9 (13.2)
Stable recent living situation 76 (77.6) 132 (81.0) 91 (75.2) 28 (87.5) 43 (81.1) 49 (71.0)
Eats most meals alone 36 (38.7)** 76 (47.2) 76 (63.3) 6 (19.4) 18 (34.0) 30 (44.1)
East with someone else 57 (61.3) 85 (52.8) 44 (36.7) 25 (80.6) 35 (66.0) 38 (55.9)
Recent living situation, past 4 weeks
Homeless 12 (12.2) 16 (9.7) 15 (12.3) 1 (3.1) 1 (1.9) 11 (15.9)
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Table 2 Overall quality of life (QoL) of patients entering substance use disorder treatment in Norway, 2012–2015 (Continued)
Temporary housing 5 (5.1) 2 (1.2) 8 (6.6) 4 (12.5) 2 (3.8) 5 (7.2)
Institution 25 (25.5) 44 (26.7) 26 (21.3) 7 (21.9) 10 (18.9) 14 (20.3)
Owned or rented 47 (48.0) 80 (48.5) 60 (49.2) 15 (46.9) 30 (56.6) 29 (42.0)
Other 9 (9.2) 23 (13.9) 13 (10.7) 5 (15.6) 10 (18.9) 10 (14.5)
Variables approaching significance are in bold text. ap < 0.1; *p < 0.05; **p < 0.01
QoL Quality of life, OMT opioid maintenance treatment,SUD substance use disorder
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(p = 0.09 for both variables). Eating meals alone continued
to be a risk factor for reporting very poor QoL (RRR 2.6,
CI: 1.4–4.8) among men.
Consuming methadone/buprenorphine had a protect-
ive effect against reporting very poor QoL for men (RRR
0.4, CI: 0.2–0.9) and for women (RRR 0.2, CI: 0.0–0.6),
and a protective effect against reporting poor QoL for
men (RRR 0.5, CI: 0.3–0.9).Discussion
This analysis of incoming SUD patients in Norway shows
that physical, mental and social well-being measures were
of more consequence to QoL than SUD-specific indicators,
with the exception of a strong protective effect of using
methadone or buprenorphine. After adjusting for age and
other significant variables, depressive symptoms increase
women’s risk of reporting poorer QoL. Men who were not
physically active more often reported poorer QoL, as did
those who considered themselves underweight and those
who ate most of their meals alone (a sign of limited social
networks). These variables indicate vulnerabilities at treat-
ment entry which may warrant additional attention through
targeted mental health, physical health, and social support
interventions, and which also contextualize SUD patients
as persons susceptible to many of the same health and
social concerns as other clinical and healthy populations,
in addition to experiencing the serious effects of a SUD.
The significantly impaired QoL ratings of our sample
were consistent with other studies [2], and our sample
again shows poorer QoL than among other clinical groups
[40]. The correlation of mental health problems with low
QoL is also an established finding in the literature among
chronic disease patients and the general population as well
as among the SUD population [11, 13, 14], including in
Norway [41]. The use of methadone or buprenorphine be-
fore entering treatment was associated with reporting bet-
ter QoL, and their use was the only SUD-related indicator
with a significant association to QoL [7]. This may reflect
that these individuals were more settled, in that they did
not need to “chase” illicit short-acting opiates on the street
or buy from risky markets, and hence experienced more
stabilized lives. Methadone and buprenorphine are
prescribed in OMT in Norway, and while some of theseindividuals may not have been receiving formal prescrip-
tion of OMT medications, use of such medicines still had
positive effects on their QoL.
Few large studies have explored SUD patients’ QoL in
connection with other physical well-being indicators, in-
cluding exercise behavior, and our data show that being
physically active improves the likelihood that male pa-
tients report higher QoL. Exercising behavior is frequently
found to correlate with better QoL among other chronic
disease populations and to improve QoL [19, 20]. This
should prompt the SUD research field to utilize existing
exercise research and QoL research from non-SUD groups
when developing evidence-based treatment options, as
well as to measure and exploit the potential for exercise to
be used as a QoL-boosting activity within treatment. Exer-
cise should be integrated into treatment for the very rea-
son that this population presents with such impaired
QoL. One smaller study suggests that significant QoL
improvements can be seen even after modest doses of
exercise [42].
As with physical inactivity, men’s concerns with broader
physical self-perceptions have been negatively correlated
with quality of life among other populations. For example,
Pope et al. found that feeling too lean or insufficiently
muscular is particularly dissatisfying for university-aged
men, and we see impaired QoL among both genders in
healthy and clinical groups when preoccupied with weight
and other negative body images [43–45].
“Eating alone” as a risk factor for men’s very poor QoL
also points to the importance of normalizing social rela-
tionships and increasing social contact. Spending meal-
times alone can indicate low social participation and
limited networks among the elderly [46], particularly for
men [38], and social exclusion has been found to be cor-
related with poorer QoL among psychiatric patients
[47]. Again, the social well-being needs of SUD patients
may not be so different from other chronic disease suf-
ferers or from the non-clinical population. Many studies
have highlighted the importance of partners, families,
and other elements of social settings on women’s initiation
and maintenance of substance use [27, 29], and our data
reminds us that social exclusion can still be a source of
vulnerability for men with SUD.
Another main finding is that the negative effects of
poor physical, mental, and social well-being are a pattern
Table 3 Unadjusted and adjusted relative risk ratios (RRR) of reporting poor or very poor quality of life (QoL) by selected health,
social well-being, and substance-specific indicators
Men Women
Unadjusted RRR (%CI) Adjusted RRR (%CI) Unadjusted RRR (%CI) Adjusted RRR (%CI)
Poor QoL vs. good/neutral QoL
Age 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.1)
Clinical anxiety symptoms 1.0 (0.6–1.7) 0.7 (0.4–1.3) 1.8 (0.8–4.4) 0.9 (0.3–2.7)
Clinical depression symptoms 1.3 (0.7–2.2) 1.4 (0.7–2.6) 3.0 (1.2–7.5)** 3.3 (1.0–10.3)*
Physically inactive 1.9 (1.1–3.1)** 1.6 (0.9–2.8)a ——— ———
Weight evaluation (reference: satisfied)
Considers self underweight 2.0 (1.1–3.6)** 2.0 (1.0–3.9)* ——— ———
Considers self overweight 2.2 (1.1–4.5)** 2.0 (0.9–3.9)a ——— ———
Eats meals alone 1.4 (0.8–2.3) 1.5 (0.9–2.7) ——— ———
Social network (reference: no network) ——— ———
Substance-free 1.0 (0.5–2.2) 1.5 (0.6–3.4) ——— ———
Substance-using 1.0 (0.5–2.1) 1.1 (0.5–2.6) ——— ———
Substance user category (reference: polysubstance user)
Prescribed OMT and/or medications only ——— ——— 0.0 (-)b ———
Substance- and medication-free ——— ——— 0.0 (-)b ———
Single-substance user ——— ——— 0.4 (0.1–2.2) ———
Most used substance: methadone/buprenorphine 0.6 (0.3–1.0)a 0.5 (0.3–0.9)* 0.4 (0.2–1.8) 0.6 (0.2–1.7)
Very poor QoL vs. good/neutral QoL
Age 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.1)
Clinical anxiety symptoms 2.3 (1.3–4.0)** 1.4 (0.7–2.9) 3.1 (1.3–7.5)** 1.3 (0.4–3.8)
Clinical depression symptoms 2.3 (1.3–3.9)** 1.5 (0.8–3.1) 4.4 (1.8–10.8)** 3.8 (1.2–11.8)*
Physically inactive 2.0 (1.6–3.4)** 2.0 (1.1–3.7)*
Weight evaluation (reference: satisfied)
Considers self underweight 2.0 (1.0–3.8) 2.0 (1.1–3.7)* ——— ———
Considers self overweight 2.0 (1.0–4.1) 1.6 (0.7–3.6) ——— ———
Eats meals alone 2.7 (1.6–4.8)*** 2.6 (1.4–4.8)* ——— ———
Social network (reference: no network)
Substance-free 0.4 (0.2–0.9)** 0.7 (0.3–1.7) ——— ———
Substance-using 0.7 (0.3–1.3) 0.9 (0.4–2.1) ——— ———
Substance user category (reference: polysubstance user)
Prescribed OMT and/or medications only ——— ——— 0.0 (-)b ———
Substance- and medication-free ——— ——— 0.0 (-)b ———
Single-substance user ——— ——— 0.6 (0.1–2.6) ———
Most used substance: methadone/buprenorphine 0.5 (0.2–0.8)* 0.4 (0.2–0.9)* 0.2 (0.0–0.6)* 0.2 (0.0–0.6)*
Variables approaching significance are in bold text. ap < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001. bToo few persons to calculate RRR were in this category
QoL Quality of life, OMT opioid maintenance treatment
Muller et al. Health and Quality of Life Outcomes  (2016) 14:39 Page 7 of 10across this heterogeneous sample. In fact, these indicators
were more decisive to our sample’s QoL than having a
chronic physical condition, typical protective demographic
factors such as being employed [48], and even addiction
severity measures such as polysubstance use and recent
injecting behavior. This finding is most clearly seen amongmen, where physical inactivity and a lack of social contact
have a clear relationship to the worst QoL. The absence of
many SUD-specific correlates shows that physical and
social well-being factors, perhaps less commonly con-
sidered relevant to SUD patients by their treatment
staff, are in fact burdensome and should be addressed
Muller et al. Health and Quality of Life Outcomes  (2016) 14:39 Page 8 of 10more specifically as part of treatment. Specifically, it is
important to give patients chances and support to
prioritize their own needs and gain support for positive
activities in order to address their bodily and social
concerns.
Accessing QoL at intake can be an opportunity to
learn about patient vulnerabilities which may not be
uncovered through more objective questioning of various
pre-determined domains, or a focus limited to substance
use patterns. Our findings also support the continued
measurement of QoL during treatment to guide further
treatment plans as well as to be an outcome measure
of treatment, which for a chronic condition must be
monitored and addressed during the course of the dis-
order, at various phases, inclusive of during treatment
[49]. Knowing the variables that influence patients’
well-being can help target treatment toward patient-
identified goals, and such patient improvement may
improve treatment engagement, retention and success.
If treatment’s goal of recovery and improved well-being is
to be achieved, services must be offered on multiple levels
and empower patients to improve numerous areas of their
life, without focusing only on substance-use outcomes
[50, 51]. One such tool may be opportunities and support
for physical activity as well as developing supportive social
networks. Indeed, group-based exercise as part of treat-
ment would likely improve both physical and social
outcomes and improve QoL both directly and indirectly,
thereby enhancing recovery.
Several limitations must be recognized when interpreting
these results. The cross-sectional nature of this analysis
prohibits drawing conclusions of causation, but the associa-
tions we found support further emphasis on improving
physical and social well-being in treatment, including
through investment in longitudinal studies to assess exer-
cise’s effect on the QoL of the SUD population specifically.
There may be other significant but unmeasured associa-
tions that confounded the relationships we found to QoL;
for example, body mass index may explain the correlations
between physical inactivity and poor QoL for men. Future
studies should include larger sample sizes to thoroughly ex-
plore factors which may differentially impact women and
men. The 74 % of patients who agreed to participate may
not be representative of the entire incoming SUD patient
population and there may have been inadvertent selection
mechanisms at inclusion. However, characteristics of this
sample were similar to Norwegian patient register data
[37], and including patients up to twelve weeks after start-
ing treatment prevented the de facto exclusion of patients
in the worst shape. We therefore consider our estimates to
be conservative rather than too large. The study involved a
large geographic sample of treatment facilities, and it is to
the study’s benefit that the sample provides such heterogen-
eity with regards to substance-related characteristics.Conclusion
The characteristics that we found to be associated with
poorer quality of life in this sample of substance use dis-
order patients – reporting depressive symptoms (for
women); being physically inactive, dissatisfied with one’s
physical self, and reporting some element of social isolation
(for men) – are vulnerabilities that are not unique to this
population. Not only do these findings highlight the
importance of addressing mental health and of provid-
ing support for physical and social well-being during
treatment, but they serve as a reminder that SUD pa-
tients are vulnerable to many of the same situations
and conditions as those without a SUD. Treatment
should therefore take care to not lose sight of such factors
by prioritizing directly substance-related issues, often ex-
ternally determined to be more important. Measuring
quality of life, throughout the treatment trajectory, recog-
nizes patients as sources of such important and otherwise
uncollectable information.
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